BR112018075310A2 - metódo de tratamento de esclerose múltipla empregando um inibidor de lsd1 - Google Patents
metódo de tratamento de esclerose múltipla empregando um inibidor de lsd1Info
- Publication number
- BR112018075310A2 BR112018075310A2 BR112018075310-6A BR112018075310A BR112018075310A2 BR 112018075310 A2 BR112018075310 A2 BR 112018075310A2 BR 112018075310 A BR112018075310 A BR 112018075310A BR 112018075310 A2 BR112018075310 A2 BR 112018075310A2
- Authority
- BR
- Brazil
- Prior art keywords
- multiple sclerosis
- employing
- treating multiple
- lsd1 inhibitor
- lsd1
- Prior art date
Links
- 201000006417 multiple sclerosis Diseases 0.000 title abstract 2
- 229940123628 Lysine (K)-specific demethylase 1A inhibitor Drugs 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- XBBRLCXCBCZIOI-DLBZAZTESA-N vafidemstat Chemical compound O1C(N)=NN=C1CN[C@H]1[C@H](C=2C=CC(OCC=3C=CC=CC=3)=CC=2)C1 XBBRLCXCBCZIOI-DLBZAZTESA-N 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
- C07D271/113—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Abstract
a presente invenção refere-se a, métodos para tratamento de esclerose múltipla utilizando (-) 5-((((trans)-2-(4-(benzilóxi)fenil)ciclopropil)amino)metil)-1,3,4-oxadiazol-2-amina, ou um sal ou solvato farmaceuticamente aceitável do mesmo.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15382310 | 2015-06-12 | ||
EP15382369 | 2015-07-17 | ||
PCT/EP2016/063368 WO2016198649A1 (en) | 2015-06-12 | 2016-06-10 | Biomarkers associated with lsd1 inhibitors and uses thereof |
EPPCT/EP2016/063368 | 2016-06-10 | ||
PCT/EP2017/064206 WO2017212061A1 (en) | 2015-06-12 | 2017-06-09 | Method of treating multiple sclerosis employing a lsd1-inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112018075310A2 true BR112018075310A2 (pt) | 2019-03-19 |
Family
ID=56345081
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112018075310-6A BR112018075310A2 (pt) | 2015-06-12 | 2017-06-09 | metódo de tratamento de esclerose múltipla empregando um inibidor de lsd1 |
Country Status (22)
Country | Link |
---|---|
US (1) | US20180284095A1 (pt) |
EP (1) | EP3307909A1 (pt) |
JP (3) | JP6855466B2 (pt) |
KR (2) | KR20180011331A (pt) |
CN (2) | CN107849611A (pt) |
AU (2) | AU2016275702A1 (pt) |
BR (1) | BR112018075310A2 (pt) |
CA (1) | CA2987876A1 (pt) |
CY (1) | CY1121988T1 (pt) |
DK (1) | DK3307267T3 (pt) |
HK (1) | HK1253743A1 (pt) |
HR (1) | HRP20191121T1 (pt) |
HU (1) | HUE043954T2 (pt) |
IL (2) | IL256208A (pt) |
LT (1) | LT3307267T (pt) |
MX (2) | MX2017015922A (pt) |
MY (1) | MY190849A (pt) |
PT (1) | PT3307267T (pt) |
RU (1) | RU2768120C2 (pt) |
SG (1) | SG10201911989SA (pt) |
TR (1) | TR201909353T4 (pt) |
WO (2) | WO2016198649A1 (pt) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112014009306B1 (pt) | 2011-10-20 | 2021-07-20 | Oryzon Genomics S.A. | Compostos de (hetero)aril ciclopropilamina como inibidores de lsd1 |
EP3090998A1 (en) | 2015-05-06 | 2016-11-09 | F. Hoffmann-La Roche AG | Solid forms |
WO2016198649A1 (en) * | 2015-06-12 | 2016-12-15 | Oryzon Genomics, S.A. | Biomarkers associated with lsd1 inhibitors and uses thereof |
SG10201913331VA (en) | 2016-03-15 | 2020-03-30 | Oryzon Genomics Sa | Combinations of lsd1 inhibitors for use in the treatment of solid tumors |
WO2017157813A1 (en) | 2016-03-15 | 2017-09-21 | F. Hoffmann-La Roche Ag | Combinations of lsd1 inhibitors for the treatment of hematological malignancies |
RS58951B1 (sr) | 2016-06-10 | 2019-08-30 | Oryzon Genomics Sa | Lečenje multiple skleroze |
JP2019128317A (ja) * | 2018-01-26 | 2019-08-01 | 学校法人同志社 | 多発性硬化症の診断マーカー又は診断キット |
AU2019264231A1 (en) * | 2018-05-04 | 2020-10-22 | Oryzon Genomics, S.A. | Stable pharmaceutical formulation |
EP4024049A4 (en) * | 2019-12-19 | 2023-09-20 | Daegu Gyeongbuk Institute Of Science and Technology | BIOMARKER COMPOSITION FOR DIAGNOSING MILD COGNITIVE IMPAIRMENT USING NASAL FLUID SAMPLE AND METHOD FOR DIAGNOSING MILD COGNITIVE IMPAIRMENT USING SAME |
Family Cites Families (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
AU6168396A (en) * | 1995-06-07 | 1996-12-30 | Athena Neurosciences, Inc. | Method for identifying alzheimer's disease therapeutics usin g transgenic animal models |
EP1193261A1 (en) * | 2000-10-02 | 2002-04-03 | Warner-Lambert Company | New thiadiazoles and their use as phosphodiesterase-7 inhibitors |
CA2619005A1 (en) | 2005-08-10 | 2007-02-22 | Johns Hopkins University | Polyamines useful as anti-parasitic and anti-cancer therapeutics and as lysine-specific demethylase inhibitors |
JP2010523685A (ja) | 2007-04-13 | 2010-07-15 | ザ・ジョンズ・ホプキンス・ユニバーシティー | リジン特異的デメチラーゼ阻害剤 |
EP2361242B1 (en) | 2008-10-17 | 2018-08-01 | Oryzon Genomics, S.A. | Oxidase inhibitors and their use |
EP2389362B1 (en) | 2009-01-21 | 2019-12-11 | Oryzon Genomics, S.A. | Phenylcyclopropylamine derivatives and their medical use |
US8895526B2 (en) * | 2009-03-27 | 2014-11-25 | Cold Spring Harbor Laboratory | Identification of RNAI targets and use of RNAI for rational therapy of chemotherapy-resistant leukemia and other cancers |
US8389580B2 (en) | 2009-06-02 | 2013-03-05 | Duke University | Arylcyclopropylamines and methods of use |
EP2258865A1 (en) * | 2009-06-05 | 2010-12-08 | Universitätsklinikum Freiburg | Lysine-specific demethylase 1 (LSD1) is a biomarker for breast cancer |
JPWO2010143582A1 (ja) | 2009-06-11 | 2012-11-22 | 公立大学法人名古屋市立大学 | フェニルシクロプロピルアミン誘導体及びlsd1阻害剤 |
US9708255B2 (en) | 2009-08-18 | 2017-07-18 | Robert A. Casero | (bis)urea and (bis)thiourea compounds as epigenic modulators of lysine-specific demethylase 1 and methods of treating disorders |
CN102639496B (zh) | 2009-09-25 | 2014-10-29 | 奥瑞泽恩基因组学股份有限公司 | 赖氨酸特异性脱甲基酶-1抑制剂及其应用 |
US8946296B2 (en) | 2009-10-09 | 2015-02-03 | Oryzon Genomics S.A. | Substituted heteroaryl- and aryl-cyclopropylamine acetamides and their use |
EP2560947B1 (en) | 2010-04-19 | 2016-10-12 | Oryzon Genomics, S.A. | Lysine specific demethylase-1 inhibitors and their use |
JP5934184B2 (ja) | 2010-04-20 | 2016-06-15 | ウニヴェルシタ・デグリ・ストゥディ・ディ・ローマ・ラ・サピエンツァ | ヒストンデメチラーゼlsd1及び/又はlsd2の阻害剤としてのトラニルシプロミン誘導体 |
AU2011284688B2 (en) * | 2010-07-29 | 2015-07-16 | Oryzon Genomics S.A. | Arylcyclopropylamine based demethylase inhibitors of LSD1 and their medical use |
EP2598480B1 (en) | 2010-07-29 | 2019-04-24 | Oryzon Genomics, S.A. | Cyclopropylamine derivatives useful as lsd1 inhibitors |
WO2012034116A2 (en) | 2010-09-10 | 2012-03-15 | The Johns Hopkins University | Small molecules as epigenetic modulators of lysine-specific demethylase 1 and methods of treating disorders |
WO2012045883A1 (en) | 2010-10-08 | 2012-04-12 | Oryzon Genomics S.A. | Cyclopropylamine inhibitors of oxidases |
ES2742805T3 (es) | 2011-03-25 | 2020-02-17 | Glaxosmithkline Ip No 2 Ltd | Ciclopropilaminas como inhibidores de LSD1 |
SG2014009161A (en) | 2011-08-09 | 2014-04-28 | Takeda Pharmaceutical | Cyclopropaneamine compound |
ES2821548T3 (es) | 2011-08-15 | 2021-04-26 | Univ Utah Res Found | Análogos de (E)-N'-(1-feniletiliden) benzohidrazida sustituida como inhibidores de desmetilasas de histonas |
BR112014009306B1 (pt) | 2011-10-20 | 2021-07-20 | Oryzon Genomics S.A. | Compostos de (hetero)aril ciclopropilamina como inibidores de lsd1 |
CN107417549A (zh) | 2011-10-20 | 2017-12-01 | 奥莱松基因组股份有限公司 | 作为lsd1抑制剂的(杂)芳基环丙基胺化合物 |
CN105051005B (zh) | 2012-10-12 | 2017-06-13 | 武田药品工业株式会社 | 环丙胺化合物及其用途 |
JP6238908B2 (ja) | 2012-11-28 | 2017-11-29 | 京都府公立大学法人 | リシン構造を有するlsd1選択的阻害薬 |
EP2740474A1 (en) | 2012-12-05 | 2014-06-11 | Instituto Europeo di Oncologia S.r.l. | Cyclopropylamine derivatives useful as inhibitors of histone demethylases kdm1a |
CN103054869A (zh) | 2013-01-18 | 2013-04-24 | 郑州大学 | 含***基的氨基二硫代甲酸酯化合物在制备以lsd1为靶标药物中的应用 |
WO2014164867A1 (en) | 2013-03-11 | 2014-10-09 | Imago Biosciences | Kdm1a inhibitors for the treatment of disease |
EP3003301B1 (en) | 2013-05-30 | 2021-02-24 | Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada, Las Vegas | Novel suicidal lsd1 inhibitors targeting sox2-expressing cancer cells |
CN110015984A (zh) | 2013-06-19 | 2019-07-16 | 犹他大学研究基金会 | 作为组蛋白去甲基化酶抑制剂的被取代的(e)-n’-(1-苯亚乙基)苯甲酰肼类似物 |
CN103319466B (zh) | 2013-07-04 | 2016-03-16 | 郑州大学 | 含香豆素母核的1,2,3-***-氨基二硫代甲酸酯化合物、制备方法及其应用 |
DK3030323T3 (da) | 2013-08-06 | 2019-07-15 | Imago Biosciences Inc | Kdm1a-inhibitorer til behandlingen af sygdom |
US9186391B2 (en) | 2013-08-29 | 2015-11-17 | Musc Foundation For Research Development | Cyclic peptide inhibitors of lysine-specific demethylase 1 |
WO2015031564A2 (en) | 2013-08-30 | 2015-03-05 | University Of Utah | Substituted-1h-benzo[d]imidazole series compounds as lysine-specfic demethylase 1 (lsd1) inhibitors |
SI3080100T1 (sl) | 2013-12-11 | 2023-04-28 | Celgene Quanticel Research, Inc. | Inhibitorji lizin specifične demetilaze-1 |
US10118903B2 (en) | 2014-02-07 | 2018-11-06 | Musc Foundation For Research Development | Aminotriazole-based KDM1A inhibitors as epigenetic modulators |
US9527835B2 (en) | 2014-02-13 | 2016-12-27 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
ES2672797T3 (es) | 2014-02-13 | 2018-06-18 | Incyte Corporation | Ciclopropilaminas como inhibidores de LSD1 |
BR112016018555B1 (pt) | 2014-02-13 | 2024-01-23 | Incyte Holdings Corporation | Ciclopropilaminas como inibidores de lsd1, seu uso, composição farmacêutica que os compreende e método de inibição de lsd1 |
TWI741478B (zh) | 2014-02-13 | 2021-10-01 | 美商英塞特控股公司 | 作為lsd1抑制劑之環丙胺 |
JP2017508798A (ja) | 2014-03-07 | 2017-03-30 | ザ ジョンズ ホプキンス ユニバーシティ | ヒストンリジン特異的デメチラーゼ(lsd1)およびヒストンデアセチラーゼ(hdac)の阻害剤 |
CN103893163B (zh) | 2014-03-28 | 2016-02-03 | 中国药科大学 | 2-([1,1′-联苯]-4-基)2-氧代乙基4-((3-氯-4-甲基苯基)氨基)-4-氧代丁酸酯在制备lsd1抑制剂药物中的应用 |
MA39732A (fr) | 2014-04-11 | 2021-05-26 | Takeda Pharmaceuticals Co | Composé de cyclopropanamine et son utilisation |
CN103961340B (zh) | 2014-04-30 | 2019-06-25 | 南通中国科学院海洋研究所海洋科学与技术研究发展中心 | 一类lsd1抑制剂及其应用 |
TWI676620B (zh) | 2014-05-01 | 2019-11-11 | 美商賽基昆堤塞爾研發公司 | 離胺酸特異性去甲基酶-1之抑制劑 |
BR112016028219B1 (pt) | 2014-05-30 | 2022-12-06 | Istituto Europeo Di Oncologia S.R.L | Composto ou composição farmacêutica para uso no tratamento ou prevenção do câncer, de uma doença infecciosa, ou de uma doença designada por aberração de metabolismo de energia celular em um indivíduo, processo para obtenção de um composto de fórmula (i) e uso do composto ou composição farmacêutica na fabricação de um medicamento para uso no tratamento ou prevenção do câncer, de uma doença infecciosa, ou de uma doença designada por aberração de metabolismo de energia celular em um indivíduo |
CN106660987B (zh) | 2014-06-27 | 2020-11-06 | 赛尔基因昆蒂赛尔研究公司 | 赖氨酸特异性脱甲基酶-1的抑制剂 |
CN104119280B (zh) | 2014-06-27 | 2016-03-16 | 郑州大学 | 含氨基类脲与端炔结构单元的嘧啶衍生物、制备方法及应用 |
EA201790082A1 (ru) | 2014-07-03 | 2017-08-31 | Селджен Квонтисел Рисёрч, Инк. | Ингибиторы лизин-специфической демитилазы-1 |
EP3164380B1 (en) | 2014-07-03 | 2022-02-09 | Celgene Quanticel Research, Inc. | Inhibitors of lysine specific demethylase-1 |
WO2016007727A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
TWI687419B (zh) | 2014-07-10 | 2020-03-11 | 美商英塞特公司 | 作為lsd1抑制劑之咪唑并吡啶及咪唑并吡嗪 |
TW201613925A (en) | 2014-07-10 | 2016-04-16 | Incyte Corp | Imidazopyrazines as LSD1 inhibitors |
US9695167B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors |
AU2015311805B2 (en) | 2014-09-05 | 2020-04-02 | Celgene Quanticel Research, Inc. | Inhibitors of lysine specific demethylase-1 |
EP2993175A1 (en) | 2014-09-05 | 2016-03-09 | IEO - Istituto Europeo di Oncologia Srl | Thienopyrroles as histone demethylase inhibitors |
WO2016198649A1 (en) * | 2015-06-12 | 2016-12-15 | Oryzon Genomics, S.A. | Biomarkers associated with lsd1 inhibitors and uses thereof |
-
2016
- 2016-06-10 WO PCT/EP2016/063368 patent/WO2016198649A1/en active Application Filing
- 2016-06-10 AU AU2016275702A patent/AU2016275702A1/en not_active Abandoned
- 2016-06-10 CA CA2987876A patent/CA2987876A1/en not_active Abandoned
- 2016-06-10 MX MX2017015922A patent/MX2017015922A/es unknown
- 2016-06-10 EP EP16734564.4A patent/EP3307909A1/en not_active Withdrawn
- 2016-06-10 CN CN201680045398.8A patent/CN107849611A/zh active Pending
- 2016-06-10 KR KR1020187001221A patent/KR20180011331A/ko unknown
- 2016-06-10 JP JP2018516634A patent/JP6855466B2/ja active Active
- 2016-06-10 US US15/735,377 patent/US20180284095A1/en not_active Abandoned
- 2016-06-10 SG SG10201911989SA patent/SG10201911989SA/en unknown
-
2017
- 2017-06-09 LT LTEP17735004.8T patent/LT3307267T/lt unknown
- 2017-06-09 AU AU2017277751A patent/AU2017277751B2/en active Active
- 2017-06-09 HU HUE17735004A patent/HUE043954T2/hu unknown
- 2017-06-09 KR KR1020187001123A patent/KR102372194B1/ko active IP Right Grant
- 2017-06-09 MY MYPI2017001810A patent/MY190849A/en unknown
- 2017-06-09 RU RU2019100037A patent/RU2768120C2/ru active
- 2017-06-09 PT PT17735004T patent/PT3307267T/pt unknown
- 2017-06-09 WO PCT/EP2017/064206 patent/WO2017212061A1/en active Application Filing
- 2017-06-09 MX MX2017015921A patent/MX2017015921A/es active IP Right Grant
- 2017-06-09 JP JP2017565305A patent/JP6411680B1/ja active Active
- 2017-06-09 TR TR2019/09353T patent/TR201909353T4/tr unknown
- 2017-06-09 CN CN201780002630.4A patent/CN107921029B/zh active Active
- 2017-06-09 BR BR112018075310-6A patent/BR112018075310A2/pt not_active Application Discontinuation
- 2017-06-09 DK DK17735004.8T patent/DK3307267T3/da active
- 2017-12-10 IL IL256208A patent/IL256208A/en unknown
- 2017-12-10 IL IL256207A patent/IL256207B/en unknown
-
2018
- 2018-09-21 JP JP2018177879A patent/JP2019023202A/ja active Pending
- 2018-10-10 HK HK18112896.0A patent/HK1253743A1/zh unknown
-
2019
- 2019-06-19 HR HRP20191121TT patent/HRP20191121T1/hr unknown
- 2019-06-26 CY CY20191100663T patent/CY1121988T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112018075310A2 (pt) | metódo de tratamento de esclerose múltipla empregando um inibidor de lsd1 | |
PH12016502382A1 (en) | Substituted indazole compounds as irak4 inhibitors | |
EA201890307A1 (ru) | Индазольные и азаиндазольные соединения как ингибиторы irak-4 | |
EA201790271A1 (ru) | Ингибиторы гликозидазы | |
WO2015200680A8 (en) | Prmt5 inhibitors and uses thereof | |
EA201691421A1 (ru) | Гетероарилы и их применение | |
AR103680A1 (es) | Inhibidores selectivos de bace1 | |
MX2016015565A (es) | Ciertos inhibidores de la proteina quinasa. | |
IL279260A (en) | KDM1A inhibitors for the treatment of diseases | |
MA52004A (fr) | Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glycopyranosidase | |
MA40059A (fr) | Inhibiteurs de la phosphatidylinositol 3-kinase | |
PH12020500211A1 (en) | Methods of treating behavior alterations | |
MA43402A (fr) | Composition pharmaceutique comprenant un inhibiteur puissant d'urat1 | |
HK1259405A1 (zh) | N-[5-(3,5-二氟-苄基)-1h-吲唑-3-基]-4-(4-甲基-哌嗪-1-基)-2-(四氫吡喃-4-基氨基)-苯甲酰胺的新晶型 | |
MX2016011105A (es) | Inhibidores de monoacilglicerol aciltransferasa 2 (mgat2) de dihidropiridinona para usarse en el tratamiento de trastornos metabolicos. | |
BR112017023225A2 (pt) | inibidor de proteína cinase | |
MX2016010973A (es) | Compuestos de aminocarbonilcarbamato. | |
CR20170050A (es) | Compuestos de azetidiniloxifenilpirrolidina | |
EP3737361A4 (en) | DIHYDROCERAMIDE DESATURASE INHIBITORS FOR THE TREATMENT OF DISEASE | |
BR112017009854A2 (pt) | composto, uso de um composto, e, método para tratamento de leucemia. | |
EA201990952A1 (ru) | ПИРИДОНОВОЕ СОЕДИНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРА c-Met | |
EA201990313A1 (ru) | Производное триазолопиразинона, пригодное в качестве ингибитора фдэ1 человека | |
MA53648A (fr) | Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glucopyranosidase | |
MX2019005723A (es) | Inhibidor del receptor del factor de crecimiento de fibroblastos 4 (fgfr4) y metodo de preparacion y uso del mismo. | |
PH12016502477B1 (en) | Novel polymorphic form of n-[2-(6-fluoro-lh-indol-3-yl)ethyl]-3-(2,2,3,3-tetrafluoropropoxy)benzylamine hydrochloride for the treatment of alzheimer`s |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |